Back to GetFilings.com



Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2004

 

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from                          to                         

 

Commission file number: 000-33001

 


 

NATUS MEDICAL INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware   77-0154833

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1501 Industrial Road, San Carlos, CA 94070

(Address of principal executive offices) (Zip Code)

 

(650) 802-0400

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

 

The number of issued and outstanding shares of the registrant’s Common Stock, $0.001 par value, as of August 9, 2004, was 17,059,561.

 



Table of Contents

NATUS MEDICAL INCORPORATED

 

TABLE OF CONTENTS

 

          Page No.

PART I.

  

FINANCIAL INFORMATION

   3

Item 1.

  

Financial Statements

   3
    

Condensed Consolidated Balance Sheets as of June 30, 2004 (unaudited) and December 31, 2003

   3
    

Condensed Consolidated Statements of Operations for the three months ended June 20, 2004 and 2003 and the six months ended June 30, 2004 and 2003 (unaudited)

   4
    

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2004 and 2003 (unaudited)

   5
    

Notes to Condensed Consolidated Financial Statements

   6

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

   11

Item 3.

  

Quantitative and Qualitative Disclosures about Market Risk

   30

Item 4.

  

Controls and Procedures

   31

PART II.

  

OTHER INFORMATION

   32

Item 2.

  

Changes in Securities and Use of Proceeds

   32

Item 4.

  

Submission of Matters to a Vote of Security Holders

   32

Item 6.

  

Exhibits and Reports on Form 8-K

   32

Signatures

   33

 

2


Table of Contents

PART I.    FINANCIAL INFORMATION

 

Item 1.    Financial Statements

 

NATUS MEDICAL INCORPORATED

 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share amounts)

 

    

June 30,

2004


    December 31,
2003(1)


 
     (unaudited)        
ASSETS                 

Current assets:

                

Cash and cash equivalents

   $ 5,897     $ 9,435  

Short-term investments

     32,744       28,200  

Accounts receivable, net of allowance for doubtful accounts of $421 and $395

     4,466       5,682  

Inventories

     3,956       5,263  

Prepaid expenses and other current assets

     449       528  
    


 


Total current assets

     47,512       49,108  

Property and equipment, net

     2,355       2,668  

Long-term investment

     —         341  

Deposits and other assets

     47       111  

Intangible assets

     3,448       3,594  

Goodwill

     1,194       1,198  
    


 


Total assets

   $ 54,556     $ 57,020  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY                 

Liabilities:

                

Accounts payable

   $ 1,596     $ 1,659  

Accrued liabilities

     3,503       2,229  

Deferred revenue

     312       500  
    


 


Total current liabilities

     5,411       4,388  
    


 


Commitments and contingencies

     —         —    

Stockholders’ equity:

                

Common stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding: 16,752,117 and 16,511,874

     87,839       87,038  

Treasury stock

     (307 )     —    

Deferred stock compensation

     (7 )     (33 )

Accumulated deficit

     (38,567 )     (34,495 )

Accumulated other comprehensive income

     187       122  
    


 


Total stockholders’ equity

     49,145       52,632  
    


 


Total liabilities and stockholders’ equity

   $ 54,556     $ 57,020  
    


 



(1)   Derived from the consolidated audited financial statements at December 31, 2003.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3


Table of Contents

NATUS MEDICAL INCORPORATED

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

 

    

Three Months Ended

June 30,


    Six Months Ended
June 30,


 
     2004

    2003

    2004

    2003

 

Revenue

   $ 8,398     $ 7,063     $ 16,969     $ 13,724  

Cost of revenue

     3,748       2,848       7,506       5,360  
    


 


 


 


Gross margin

     4,650       4,215       9,463       8,364  
    


 


 


 


Operating expenses:

                                

Marketing and selling

     3,110       3,428       6,081       6,485  

Research and development

     1,072       820       1,978       1,851  

General and administrative

     2,655       1,338       4,024       2,483  

Restructuring

     776       —         776       —    
    


 


 


 


Total operating expenses

     7,613       5,586       12,859       10,819  
    


 


 


 


Loss from operations

     (2,963 )     (1,371 )     (3,396 )     (2,455 )

Interest income

     99       165       196       328  

Interest expense

     —         (3 )     (3 )     (6 )

Other income (expense), net

     (177 )     15       (101 )     22  
    


 


 


 


Loss before provision for income taxes

     (3,041 )     (1,194 )     (3,304 )     (2,111 )

Provision for income taxes

     —         1       1       1  
    


 


 


 


Loss from continuing operations

     (3,041 )     (1,195 )     (3,305 )     (2,112 )

Discontinued operations

     (584 )     —         (767 )     —    
    


 


 


 


Net loss

   $ (3,625 )   $ (1,195 )   $ (4,072 )   $ (2,112 )
    


 


 


 


Basic and diluted net loss per share from continuing operations

   $ (0.18 )   $ (0.07 )   $ (0.20 )   $ (0.13 )
    


 


 


 


Basic and diluted net loss per share

   $ (0.22 )   $ (0.07 )   $ (0.24 )   $ (0.13 )
    


 


 


 


Shares used in computing basic and diluted net loss per share

     16,638       16,360       16,673       16,355  

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4


Table of Contents

NATUS MEDICAL INCORPORATED

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

    

Six Months Ended

June 30,


 
     2004

    2003

 

Operating activities:

                

Net loss from continuing operations

   $ (3,305 )   $ (2,112 )

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

                

Depreciation and amortization

     809       617  

Stock-based compensation

     378       129  

Loss on disposal of assets

     175       6  

Changes in operating assets and liabilities:

                

Accounts receivable

     1,378       1,118  

Inventories

     1,256       (861 )

Prepaid expenses and other current assets

     82       (157 )

Accounts payable

     (79 )     (387 )

Accrued liabilities and deferred revenue

     1,079       (6 )
    


 


Net cash provided by (used in) continuing operations

     1,773       (1,653 )

Net cash used in discontinued operations

     (406 )     —    
    


 


Net cash provided by (used in) operating activities

     1,367       (1,653 )
    


 


Investing activities:

                

Acquisition of property and equipment

     (851 )     (224 )

Deposits and other assets

     71       (3 )

Purchases of short-term investments

     (31,975 )     (28,501 )

Sales of short-term investments

     27,500       25,611  

Purchase of long-term investments

     340       —    
    


 


Net cash used in continuing operations

     (4,915 )     (3,117 )

Net cash used in discontinued operations

     (129 )     —    
    


 


Net cash used in investing activities

     (5,044 )     (3,117 )
    


 


Financing activities:

                

Issuance of common stock

     449       356  

Purchase of treasury stock

     (307 )     —    
    


 


Net cash provided by financing activities

     142       356  
    


 


Exchange rate effect on cash and cash equivalents

     (3 )     (74 )
    


 


Net decrease in cash and cash equivalents

     (3,538 )     (4,488 )

Cash and cash equivalents, beginning of period

     9,435       17,768  
    


 


Cash and cash equivalents, end of period

   $ 5,897     $ 13,280  
    


 


Non-cash investing and financing activities:

                

Reversal of deferred stock compensation relating to cancellation of stock options

   $ 20     $ —    
    


 


Stock compensation relating to accelerated vesting of stock options

   $ 352     $ —